We have located links that may give you full text access.
Residual neuromuscular blockade in a real life clinical setting: correlation with sugammadex or neostigmine administration.
Minerva Anestesiologica 2016 May
BACKGROUND: The aim of this study was to identify the frequency of residual neuromuscular blockade (RNMB) in the postanesthesia care unit (PACU) of a tertiary university hospital in Greece, and its correlation with reversal agents. The influence of other perioperative factors was assessed secondarily.
METHODS: Patients >18 years old, undergoing surgery with general anesthesia were prospectively studied during a 6-month period. Immediately after arrival at the PACU, the train-of-four ratio (TOF) was assessed by independent investigators, using accelerometry 3 consecutive times, and the mean value was calculated. When TOF was <0.9, RNMB was diagnosed and further interventions were decided. All perioperative data, including history of patients, anesthetic drugs used and surgical details, were recorded from the patients' files.
RESULTS: Five hundred twenty patients were studied; 90.4% received rocuronium, 9.2% cis-atracurium, and 0.4% succinylcholine. The prevalence of RNMB was 10.8%. A significant difference (P=0.0006) was detected between patients who received neostigmine versus sugammadex, with the latter showing higher TOF values postoperatively, although the actual incidence of RNMB did not differ between the two groups. Patients with coexisting diseases received sugammadex more frequently (P<0.001), while women, and patients ASA>III were more likely to exhibit RNMB (P=0.02 and P=0.05 respectively).
CONCLUSIONS: The frequency of RNMB was 10.8%. Patients who received sugammadex presented with higher TOF values at the PACU, although no difference in RNMB was detected compared to neostigmine. Female gender and the presence of comorbidities increased the possibility to exhibit RNMB at the PACU.
METHODS: Patients >18 years old, undergoing surgery with general anesthesia were prospectively studied during a 6-month period. Immediately after arrival at the PACU, the train-of-four ratio (TOF) was assessed by independent investigators, using accelerometry 3 consecutive times, and the mean value was calculated. When TOF was <0.9, RNMB was diagnosed and further interventions were decided. All perioperative data, including history of patients, anesthetic drugs used and surgical details, were recorded from the patients' files.
RESULTS: Five hundred twenty patients were studied; 90.4% received rocuronium, 9.2% cis-atracurium, and 0.4% succinylcholine. The prevalence of RNMB was 10.8%. A significant difference (P=0.0006) was detected between patients who received neostigmine versus sugammadex, with the latter showing higher TOF values postoperatively, although the actual incidence of RNMB did not differ between the two groups. Patients with coexisting diseases received sugammadex more frequently (P<0.001), while women, and patients ASA>III were more likely to exhibit RNMB (P=0.02 and P=0.05 respectively).
CONCLUSIONS: The frequency of RNMB was 10.8%. Patients who received sugammadex presented with higher TOF values at the PACU, although no difference in RNMB was detected compared to neostigmine. Female gender and the presence of comorbidities increased the possibility to exhibit RNMB at the PACU.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app